{"ticker": {"uuid": "14e61665-c4d3-422b-8a47-fc7ca03b3bee", "symbol": "ABVX", "name": "Abivax SA American Depositary Shares", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQQUJPVE1zM0hhUWYzLVUwWXQ1aW42X1NSLW9UVEVMZGcwSU8yWjhRejlFaG5aUmVsejlWSjI0eEhIVDlleHVMWllEQXh2V29Pcm1RWVZUWDNWbVh5d1BCZkx1ZGo4VzFNWlBXTWZhY2J5QXdEQ1RlWEpHMXRIWnMxQUVOcDBuUWxRempKTllTVzNfbklrck5LZ21qSWtYRnc3ZjNxb1RVZTM2a3NsNUt3b2xPazdGMDZCTnJURjQ5VDEwZHg3Q3Y0c013?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T09:17:47+00:00", "published_display": "21 Jul 2026 09:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Principal Financial Group Inc. Increases Holdings in Abivax SA Sponsored ADR $ABVX", "summary": "Principal Financial Group Inc. significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 43.3% in the first quarter, bringing its total holdings to 312,274 shares valued at approximately $34.8 million. Other institutional investors have also adjusted their pos", "url": "https://www.marketbeat.com/instant-alerts/filing-principal-financial-group-inc-increases-holdings-in-abivax-sa-sponsored-adr-abvx-2026-07-19/", "source_name": "MarketBeat", "published_at": "2026-07-19T08:40:22", "published_display": "19 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. (NASDAQ:ABVX) following a drop in stock price. This investigation comes after Abivax announced on June 2, 2026, that its Phase 3 ABTECT clinical trial for obefazimod reveal", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-abivax-sa-abvx-and-encourages-0", "source_name": "The National Law Review", "published_at": "2026-07-18T02:39:18", "published_display": "18 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brummer Multi Strategy AB Boosts Position in Abivax SA Sponsored ADR $ABVX", "summary": "Brummer Multi Strategy AB significantly increased its stake in Abivax SA, boosting its holdings by 56% to 22,428 shares, now representing 10.4% of its portfolio. This move aligns with a \"Moderate Buy\" consensus from analysts, who have set price targets as high as $187. Abivax rec", "url": "https://www.marketbeat.com/instant-alerts/filing-brummer-multi-strategy-ab-boosts-position-in-abivax-sa-sponsored-adr-abvx-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T08:41:38", "published_display": "17 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates", "summary": "Valerio Therapeutics and Abivax have announced a research and development agreement to identify new drug candidates for inflammatory diseases. The collaboration aims to leverage the expertise of both companies to advance treatment options in this therapeutic area.", "url": "https://www.moomoo.com/news/post/73069029/valerio-therapeutics-abivax-sign-r-d-deal-for-inflammatory-diseases?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T02:10:13", "published_display": "17 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valerio-therapeutics-abivax-enter-r-100843732.html", "source_name": "MT Newswires", "published_at": "2026-07-16T10:08:43+00:00", "published_display": "16 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valerio-therapeutics-announces-development-collaboration-070700252.html", "source_name": "Business Wire", "published_at": "2026-07-16T07:07:00+00:00", "published_display": "16 Jul 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax bowel-disease drug hits goals in trial, but shares plunge on safety worries", "summary": "Abivax's experimental drug obefazotide met its primary and secondary endpoints in a late-stage trial for ulcerative colitis, showing significant clinical remission and endoscopic improvement. Despite the positive efficacy results, the company's shares plunged due to concerns over", "url": "https://www.msn.com/en-us/health/other/abivax-bowel-disease-drug-hits-goals-in-trial-but-shares-plunge-on-safety-worries/ar-AA24Cy7l?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-07-16T02:40:15", "published_display": "16 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Diversify Wealth Management LLC Purchases 14,626 Shares of Abivax SA Sponsored ADR $ABVX", "summary": "Diversify Wealth Management LLC significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the first quarter by 470.3%, acquiring an additional 14,626 shares. This brings their total holding to 17,736 shares, valued at approximately $1.88 million. Abivax re", "url": "https://www.marketbeat.com/instant-alerts/filing-diversify-wealth-management-llc-purchases-14626-shares-of-abivax-sa-sponsored-adr-abvx-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T08:14:27", "published_display": "15 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX (ABVX) Corporate presentation Summary", "summary": "The corporate presentation summary for ABIVAX (ABVX) highlights its drug obefazimod, currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b for Crohn's disease (CD), with key data expected through mid-2027. Obefazimod, an oral small molecule enhancing miR-124, targe", "url": "https://quartr.com/events/abivax-soci-t-anonyme-abvx-corporate-presentation_Fem8jdPx", "source_name": "Quartr", "published_at": "2026-07-15T01:41:05", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Takes $4.01 Million Position in Abivax SA Sponsored ADR $ABVX", "summary": "Candriam S.C.A. has initiated a significant position in Abivax SA Sponsored ADR (NASDAQ:ABVX), acquiring 36,061 shares valued at approximately $4.01 million in the first quarter. This move comes as other institutional investors like Millennium Management and Woodline Partners hav", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-takes-401-million-position-in-abivax-sa-sponsored-adr-abvx-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:12:05", "published_display": "14 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax sinks as cancer cases mar crucial bowel disease study", "summary": "Abivax's stock fell sharply due to a higher-than-expected rate of cancer cases in its ulcerative colitis drug study, raising safety concerns. Despite the company stating the cases were not drug-related, investors reacted negatively to the news, particularly concerning a medicatio", "url": "https://www.msn.com/en-us/health/other/abivax-sinks-as-cancer-cases-mar-crucial-bowel-disease-study/ar-AA24zMbd?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-13T14:41:10", "published_display": "13 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Precision Trading with Abivax Sa (ABVX) Risk Zones", "summary": "This article provides a precision trading analysis for Abivax Sa (ABVX), highlighting a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It outlines three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014wit", "url": "https://news.stocktradersdaily.com/news_release/14/Precision_Trading_with_Abivax_Sa_ABVX_Risk_Zones_071226084602_1783860362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T08:46:00", "published_display": "12 Jul 2026 08:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Could Be 44% Undervalued As UC Data Lands", "summary": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) is considered 44% undervalued by analysts, trading below its implied fair value of \u20ac220 despite a recent share price run and new positive data for its ulcerative colitis candidate, obefazimod. The company has also secured sufficient funding fo", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-abvx/abivax-societe-anonyme-shares/news/abivax-socit-anonyme-enxtpaabvx-could-be-44-undervalued-as-u", "source_name": "Simply Wall Street", "published_at": "2026-07-11T00:11:04", "published_display": "11 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-abivax-sa-sponsored-adr-135501149.html", "source_name": "Zacks", "published_at": "2026-07-10T13:55:01+00:00", "published_display": "10 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma", "summary": "Abivax CEO Marc de Garidel announced that a recent $920 million share offering provides the company with sufficient funds to independently launch its bowel disease drug, obefazimod, in the U.S. through 2029. This funding allows them to avoid partnering with a larger pharmaceutica", "url": "https://qz.com/abivax-ceo-920-million-raise-us-drug-launch-solo-071026", "source_name": "Quartz", "published_at": "2026-07-10T14:39:34", "published_display": "10 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler raises Abivax stock price target to $175 on UC data", "summary": "Piper Sandler has increased its price target for Abivax (NASDAQ: ABVX) to $175 from $165, maintaining an Overweight rating, following positive ulcerative colitis data and recent equity financing. The firm boosted its 2035 U.S. ulcerative colitis revenue estimates for obefazimod t", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-raises-abivax-stock-price-target-to-175-on-uc-data-93CH-4784521", "source_name": "Investing.com", "published_at": "2026-07-10T11:40:34", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC", "summary": "Abivax secured $920 million in funding, allowing the French biotech to independently launch its bowel disease drug, obefazimod, in the U.S. without needing a Big Pharma acquisition. CEO Marc de Garidel stated this funding provides cash until late 2029 and positions the company fo", "url": "https://www.cnbc.com/2026/07/10/abivax-stock-takeover-us-launch-obefazimod-ulcerative-colitis.html", "source_name": "CNBC", "published_at": "2026-07-10T10:12:42", "published_display": "10 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Best defense is the offence, says Abivax CEO after takeover speculation", "summary": "Abivax CEO Marc de Garidel discussed the company's clinical trials and recent takeover speculation. He stated that \"Best defense is the offense\" in response to questions about the company's strategy amid these speculations.", "url": "https://www.cnbc.com/video/2026/07/10/abivax-ceo-best-defense-is-the-offence.html", "source_name": "CNBC", "published_at": "2026-07-10T10:12:42", "published_display": "10 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax: Wall Street Catches Up to the Data", "summary": "Shares of Abivax (NASDAQ: ABVX) surged over 40% after positive Phase 3 trial results for its ulcerative colitis drug, Obefazimod, and a successful $920 million share offering. Despite an initial dip due to a cancer-related safety signal, subsequent data reinforced the drug's safe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/3188479/abivax-wall-street-catches-up-to-the-data/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sofinnova Crossover I cuts Abivax (ABVX) holding to 3.1% after share sales", "summary": "Sofinnova Crossover I SLP and related parties have reduced their stake in Abivax S.A. (ABVX) to approximately 3.1% of outstanding ordinary shares. This reduction followed a series of open-market sales of American Depositary Shares (ADSs) and ordinary shares between June 30 and Ju", "url": "https://www.stocktitan.net/sec-filings/ABVX/schedule-13d-a-abivax-s-a-amended-major-shareholder-report-63900733e297.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:40:49", "published_display": "07 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Closes $920 Million ADS Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/abivax-closes-920-million-ads-202120337.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:21:20+00:00", "published_display": "06 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Announces Closing of $920 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abivax-announces-closing-920-million-200500963.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:05:00+00:00", "published_display": "06 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abivax-rebounds-obefazimod-unlikely-replace-151247990.html", "source_name": "MT Newswires", "published_at": "2026-07-06T15:12:47+00:00", "published_display": "06 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Abivax to $140 From $110, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-abivax-105235369.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:52:35+00:00", "published_display": "06 Jul 2026 10:52", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: New UC Data Sparks Smoother Sailing for Abivax", "summary": "Shares of French biotech company Abivax surged after the company released positive new data from its Phase III maintenance program for obefazimod, its lead candidate for ulcerative colitis. The data showed meaningful clinical benefit and, crucially, no new safety signals, easing ", "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-new-uc-data-sparks-smoother-sailing-for-abivax/", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-07-05T21:16:12", "published_display": "05 Jul 2026 21:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNY2FmMkpYbDMyZnhPRVVuODMzNEFXNTdtNGtUeDd4MHJaOHZBWHh4cDZiUDRpSmZ1cm9Oa0VjcXdKLUJSbVNFMzRRc290Zk5ybWZlU05JOVVNcm55akZpdDhERFdUWjFUMDZfNnhDaHBPamd5ZlZlVFBKOEQ2RjhuX29SSXA1T3lGYk9SU2RhOEtYSm5jdGc?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Eyes Over Six-Month High As US Commercialization Plans Gain Momentum \u2013 Retail Eyes Potential Buyout", "summary": "Abivax (ABVX) shares are nearing a six-month high after underwriters fully exercised an option to purchase an additional 960,000 American depositary shares, raising total proceeds to $874.1 million. The funds will support the potential U.S. commercialization of its lead drug Obef", "url": "https://stocktwits.com/news-articles/markets/equity/why-abvx-stock-is-rising-abivax-920-million-offering/cZme09eR7S7", "source_name": "Stocktwits", "published_at": "2026-07-02T10:09:12", "published_display": "02 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Prices $800M Offering Of ADS \u2013 Here\u2019s A Look At Some Key Figures", "summary": "Abivax announced the pricing of an upsized underwritten public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, increasing the offering size from $600 million to $800 million. The company expects these proceeds, combined with existing cash, to extend its op", "url": "https://stocktwits.com/news-articles/markets/equity/abvx-stock-offering-ads-800-million/cZm3LXMR7KU", "source_name": "Stocktwits", "published_at": "2026-07-02T09:09:48", "published_display": "02 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet", "summary": "Abivax shares continued to rise after the French biotech firm announced an upsized stock offering to strengthen its balance sheet. This move follows positive clinical trial data for its lead drug, obefazimod, which is being developed to treat inflammatory bowel diseases. The comp", "url": "https://www.wsj.com/finance/stocks/abivax-shares-continue-climbing-after-biotech-firm-moves-to-bolster-balance-sheet-3c1be30a", "source_name": "WSJ", "published_at": "2026-07-02T09:09:12", "published_display": "02 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet \u2013 Buyout Chatter Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQQkRXQy1LMXZFVUlQNUJ6VmFVUEZKcmFLUHNjWFhFM0VLVFZ0UjhuNE5Xd2JTc1B0Z2hIa1lXTGRtV09FV0pGMXcwTUNoeDRSajdiSmxKQjBacVBzWEFFblVUVUpqNWwwY055M2RmRk9LQ1lkSzNSU0lIblQ2ZmVCWnhYMWx1WlBNSHUxQWQ1M3U1bXM?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares surge as worries subside over immune drug\u2019s cancer risk", "summary": "Shares of Abivax surged by nearly 40% after the release of supplementary Phase 3 data for its inflammatory bowel disease drug, obefazimod, which alleviated investor concerns about increased cancer risk. The company stated that cancer rates observed in its trials were consistent w", "url": "https://www.biopharmadive.com/news/abivax-obefazimod-Phase3-safety-data-cancer-ulcerative-colitis/824196/", "source_name": "BioPharma Dive", "published_at": "2026-07-01T22:12:12", "published_display": "01 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax stock surges on obefazimod safety data, cancer concerns", "summary": "Abivax's stock price experienced a surge following the release of safety data for its drug candidate, obefazimod. This positive development likely addressed some previous concerns, potentially including those related to cancer.", "url": "https://qz.com/abivax-stock-obefazimod-trial-data-cancer-safety-063026", "source_name": "Quartz", "published_at": "2026-07-01T21:10:30", "published_display": "01 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax raises $800M as dilution hits 8% and cash reaches 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNzA2RWlWV2VJcFB2eFI2WmtwNm1BMFVFZGhIN2dvaGhndmRNdDdaQmdaRzRyaTVWNEpNRnE3cXgtNktQSXlHekppN0pNbWM1MW41SWpWbXZtRHFNNHFBZzFyWmhLenptSXoyUGg3WXVLZXYyb29HNFduSWFlZlZPMmZTaThKdFJ2dGc1Q1AyM0sybUVHSTA3STNlNHJpTGpHV2pwZmZWS2tndWJBTHdNRTNjWjF3QnFSSkxZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From Cancer Scare to Comeback, Abivax Shares Erase a Month of Losses in a Day", "summary": "Abivax shares surged over 38% after new Phase 3 data for its ulcerative colitis drug, obefazimod, eased cancer-safety fears that had previously caused a significant stock crash. The data showed durable remission with no new safety signals, reassuring investors. While some analyst", "url": "https://finance.yahoo.com/healthcare/articles/cancer-scare-comeback-abivax-shares-045625979.html", "source_name": "Market source", "published_at": "2026-07-01T05:10:29", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more", "summary": "This article details the biggest stock movements midday, including AeroVironment's rally due to strong earnings and revenue, Abivax's surge on positive ulcerative colitis treatment data, and Watts Water Technologies' jump after an analyst upgrade. Other companies like Astera Labs", "url": "https://www.cnbc.com/2026/06/30/stocks-making-the-biggest-moves-midday-avav-abvx-alab-wts.html", "source_name": "CNBC", "published_at": "2026-06-30T17:10:29", "published_display": "30 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Whipsaws As Obefazimod Delivers Standout Phase 3 Data", "summary": "Abivax SA (ABVX) stock experienced significant volatility, whipsawing after announcing positive Phase 3 data for its ulcerative colitis drug, obefazimod. The drug showed strong remission rates compared to placebo, meeting key endpoints, but concerns about malignancy cases at the ", "url": "https://stockstotrade.com/news/abivax-sa-abvx-news-2026_06_30-2/", "source_name": "StocksToTrade", "published_at": "2026-06-30T16:10:29", "published_display": "30 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares jump as updated trial data eases safety concerns", "summary": "Abivax shares surged over 40% after releasing updated safety data for its investigational ulcerative colitis drug, obefazimod. The new analysis showed malignancy rates consistent with background rates in ulcerative colitis patients, easing previous safety concerns that had caused", "url": "https://www.proactiveinvestors.com/companies/news/1094736/abivax-shares-jump-as-updated-trial-data-eases-safety-concerns-1094736.html", "source_name": "Proactive financial news", "published_at": "2026-06-30T13:15:00", "published_display": "30 Jun 2026 13:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Slides as Investors Continue to Weigh Obefazimod Safety Questions | ABVX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQOFduOWFvX2RveHI2N0VNSzA2Y3k5YVB4Rm4xNEw0UWhDV2NKejdMYkVyRWM0TndyNjVsUzhodmRScF9IOE42dEJjUVh6N0JCNVJrb1E5ZnJSa2JFTzJBV2I2VTNoZlM2UWVVNzhyM2FIdTEwS0laWGx6RHhFU0JWUk1YRmVsVHVnYW5ra091R3ZzVWxGblFMSk00X2w2SGptY1NRU3d2dlo?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax (ABVX) Jumps 16% on Bargain-Hunting", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOUTdTalFmbGFneHFEUGVNTU9NeHQ4NjQ1aHdTa2JRdlphcWFWSl9zcUJvUDd0Y1FZMHMtemdhckFWaF80UzVmWUpwSFRqcDNaSzFjWmdGeFI2N2pIcU9wb3AxQlRNVDg1a09DOEpTa0p2bEh3S0FsMVppMHVLdlV4aXhmQ0hIM3BkUTItbDQyWTlKb0tzMDcySA?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQb0dRd05xclZYOWRvTjVNdS1wWVJFRkhDVnRqMHVjR3V5a29OOFBVTUtydFlpel9zYVJyeF9PQWY4b1l6c2NYQ2c0Z2F2OU0yS25QMlJVeV9FUEE4QlAtX2N0OHhfdzZWeV9DSnI4ZEJoa3dON0M3UGE3ZzhSd0lHckMtem9LLURkOEZjcGl5c0N5UzVQXzhleQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Drops 32% On Cancer Signal: Jefferies Warns Of \u2018Real\u2019 Overhang But Retail Calls Selloff An \u2018Overreaction\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNNGg1aFFHdVVCTWdMbnFlX1hVamZMcTU2ZWt5WDFJekhCSW00NnVqZmp3UW55UHQ4b1FMYnUyUm9SamRUUTQxNnY0YkVROC1DUkZpUjZVSXB3eTFlUnFfbTRTY2dESXJ5c1lZMjM0ZnM3X2E2cW5uTzRqc0NCXzEzOHRFbG9UdXJYcVE1bGExV29zYjl6ZnNzVzRB?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares sink after key trial results for inflammatory bowel drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQLUdsbXNZM0dVUzlnZmd1TEhBLVUxcjR6RFZZY0RleU1seXhjTktWN0xKcHhzbENpRXl4dXNmN19NbEVTdVFMVFpXV1dHQ2ItYUFWTHdyR1laUlFQd1NRWTBwWklSZ3RpMXdfN0xGVlhKQVFvanZBbENvNnlna3NrVHVaTXFNWHh5VFVCLU1jZEhuaUZVeG5abU1yb3N3S1NFUUJnOGVZZl9renN1a2N4WVFIVXRVR0J6aTlWWnRvUlZZLXVKY0kyeGNNN203bGR3TVR4Sg?oc=5", "source_name": "Reuters", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQYXVfVjVSdXNiYmluVFFXbGZMaVZuMVp1RE9xQ0NfXzA5QUljd25GVjI0Tzh4VERiXzZpVUxDN3ZPa21MYUlVc0xKVkxMX212QnFLa3haRXZkTFIxR05pb01CN0FhRmVtdGQtRnVERkdZUmY5MmhXRHF3X0laR1o0ZDdJcUtGYnprdVlkaFJkcUx0bWdLcDlIblVn?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Is Up 6.9% After Long-Term Obefazimod Data And Q1 Results - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMHVvVkFYSTg1NFFXYk42QkFUX1YyLXZvY0dSSHJnQkxSZzcyZmY2Z1phOTJiWVhnZFdlbjJLaEJsekl6UFZYNTlkMklkeUNFT1dfREpNMHowbDZ1QXRkWTBHMDU4aWVHQzNWdGRJd1FITk5zd1VtVGhxV2otNUI2WHNLOExORWxEZzFDMVRBeTNWOVF3cGtrSkV2QWRSZw?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Valuation After Recent Share Price Softness And Conflicting Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcF9UUjJDZHVTaHo3ZHRaaUFnWkVrdlk3RmhCVmVFTDZ3d3l1a2FIdjgzYTlTUzh4MjA3aWMtWWM2cTJsY28xTlF3em1NSHZ4Z3liNWZYVktWdGUyMVlLQ3lPd3JiVHVBaVRMYlAxNjJRR3c0YnpmOXIzdEZFM282U3ktRWI3T2RZc0Vwam5GWTAwVjB3RGs3VFp5blM?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty Certificates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSUpYNU8yV3kyVVF2NXZnNU1MMWtXRnNCakFfQ3lnREE4a2c5bnNOU2xBS2VXZnU4R25nekY3bnY3UWhQY0wtWmxqa01PV1d3NHlQQzZ2ODRENkZuclNpQ2p5ZmxtdDFTQ09FZ3RtQUlSOV9JSU1mN2sxcktqRG9BT0J0TlVaSEotdWViYUFRaW9mZnVaSW5MWU1vTHhCODlURWc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaE5ybTFpYkl2V3hUTkJGRmh6Q0xqaTZPbzN3TTFlT3hjd3hudWF0TGI2aEdCemtnSjNndVduRFAyNmdhN2ZLWnNXeG02NkVBRDlraElPbDU5VlVLZENOYno2NnFOUEprVWVxdEl3SzB2WE1tam5BOVhNM2Z0YlRSdm9GVXZKVXBHODFCVGJxVWVzOVR1TVJjeUhHN2RPd3dTU3B0Q2lR?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQQUJPVE1zM0hhUWYzLVUwWXQ1aW42X1NSLW9UVEVMZGcwSU8yWjhRejlFaG5aUmVsejlWSjI0eEhIVDlleHVMWllEQXh2V29Pcm1RWVZUWDNWbVh5d1BCZkx1ZGo4VzFNWlBXTWZhY2J5QXdEQ1RlWEpHMXRIWnMxQUVOcDBuUWxRempKTllTVzNfbklrck5LZ21qSWtYRnc3ZjNxb1RVZTM2a3NsNUt3b2xPazdGMDZCTnJURjQ5VDEwZHg3Q3Y0c013?oc=5", "source_name": "MarketBeat", "published_at": "2026-07-21T09:17:47+00:00", "published_display": "21 Jul 2026 09:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Principal Financial Group Inc. Increases Holdings in Abivax SA Sponsored ADR $ABVX", "summary": "Principal Financial Group Inc. significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 43.3% in the first quarter, bringing its total holdings to 312,274 shares valued at approximately $34.8 million. Other institutional investors have also adjusted their pos", "url": "https://www.marketbeat.com/instant-alerts/filing-principal-financial-group-inc-increases-holdings-in-abivax-sa-sponsored-adr-abvx-2026-07-19/", "source_name": "MarketBeat", "published_at": "2026-07-19T08:40:22", "published_display": "19 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Abivax S.A. (ABVX) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Abivax S.A. (NASDAQ:ABVX) following a drop in stock price. This investigation comes after Abivax announced on June 2, 2026, that its Phase 3 ABTECT clinical trial for obefazimod reveal", "url": "https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-abivax-sa-abvx-and-encourages-0", "source_name": "The National Law Review", "published_at": "2026-07-18T02:39:18", "published_display": "18 Jul 2026 02:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Brummer Multi Strategy AB Boosts Position in Abivax SA Sponsored ADR $ABVX", "summary": "Brummer Multi Strategy AB significantly increased its stake in Abivax SA, boosting its holdings by 56% to 22,428 shares, now representing 10.4% of its portfolio. This move aligns with a \"Moderate Buy\" consensus from analysts, who have set price targets as high as $187. Abivax rec", "url": "https://www.marketbeat.com/instant-alerts/filing-brummer-multi-strategy-ab-boosts-position-in-abivax-sa-sponsored-adr-abvx-2026-07-17/", "source_name": "MarketBeat", "published_at": "2026-07-17T08:41:38", "published_display": "17 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valerio Therapeutics, Abivax Sign R&D Deal for Inflammatory Diseases' Drug Candidates", "summary": "Valerio Therapeutics and Abivax have announced a research and development agreement to identify new drug candidates for inflammatory diseases. The collaboration aims to leverage the expertise of both companies to advance treatment options in this therapeutic area.", "url": "https://www.moomoo.com/news/post/73069029/valerio-therapeutics-abivax-sign-r-d-deal-for-inflammatory-diseases?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-17T02:10:13", "published_display": "17 Jul 2026 02:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valerio-therapeutics-abivax-enter-r-100843732.html", "source_name": "MT Newswires", "published_at": "2026-07-16T10:08:43+00:00", "published_display": "16 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Valerio Therapeutics Announces Development Collaboration with Abivax and Provides Pipeline Update", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/valerio-therapeutics-announces-development-collaboration-070700252.html", "source_name": "Business Wire", "published_at": "2026-07-16T07:07:00+00:00", "published_display": "16 Jul 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax bowel-disease drug hits goals in trial, but shares plunge on safety worries", "summary": "Abivax's experimental drug obefazotide met its primary and secondary endpoints in a late-stage trial for ulcerative colitis, showing significant clinical remission and endoscopic improvement. Despite the positive efficacy results, the company's shares plunged due to concerns over", "url": "https://www.msn.com/en-us/health/other/abivax-bowel-disease-drug-hits-goals-in-trial-but-shares-plunge-on-safety-worries/ar-AA24Cy7l?ocid=BingNewsVerp", "source_name": "MSN", "published_at": "2026-07-16T02:40:15", "published_display": "16 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Diversify Wealth Management LLC Purchases 14,626 Shares of Abivax SA Sponsored ADR $ABVX", "summary": "Diversify Wealth Management LLC significantly increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the first quarter by 470.3%, acquiring an additional 14,626 shares. This brings their total holding to 17,736 shares, valued at approximately $1.88 million. Abivax re", "url": "https://www.marketbeat.com/instant-alerts/filing-diversify-wealth-management-llc-purchases-14626-shares-of-abivax-sa-sponsored-adr-abvx-2026-07-15/", "source_name": "MarketBeat", "published_at": "2026-07-15T08:14:27", "published_display": "15 Jul 2026 08:14", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX (ABVX) Corporate presentation Summary", "summary": "The corporate presentation summary for ABIVAX (ABVX) highlights its drug obefazimod, currently in Phase 3 trials for ulcerative colitis (UC) and Phase 2b for Crohn's disease (CD), with key data expected through mid-2027. Obefazimod, an oral small molecule enhancing miR-124, targe", "url": "https://quartr.com/events/abivax-soci-t-anonyme-abvx-corporate-presentation_Fem8jdPx", "source_name": "Quartr", "published_at": "2026-07-15T01:41:05", "published_display": "15 Jul 2026 01:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Candriam S.C.A. Takes $4.01 Million Position in Abivax SA Sponsored ADR $ABVX", "summary": "Candriam S.C.A. has initiated a significant position in Abivax SA Sponsored ADR (NASDAQ:ABVX), acquiring 36,061 shares valued at approximately $4.01 million in the first quarter. This move comes as other institutional investors like Millennium Management and Woodline Partners hav", "url": "https://www.marketbeat.com/instant-alerts/filing-candriam-sca-takes-401-million-position-in-abivax-sa-sponsored-adr-abvx-2026-07-14/", "source_name": "MarketBeat", "published_at": "2026-07-14T08:12:05", "published_display": "14 Jul 2026 08:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax sinks as cancer cases mar crucial bowel disease study", "summary": "Abivax's stock fell sharply due to a higher-than-expected rate of cancer cases in its ulcerative colitis drug study, raising safety concerns. Despite the company stating the cases were not drug-related, investors reacted negatively to the news, particularly concerning a medicatio", "url": "https://www.msn.com/en-us/health/other/abivax-sinks-as-cancer-cases-mar-crucial-bowel-disease-study/ar-AA24zMbd?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-13T14:41:10", "published_display": "13 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 25, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Abivax Sa (ABVX) Risk Zones", "summary": "This article provides a precision trading analysis for Abivax Sa (ABVX), highlighting a weak near-term sentiment that could precede shifts in its mid and long-term outlook. It outlines three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014wit", "url": "https://news.stocktradersdaily.com/news_release/14/Precision_Trading_with_Abivax_Sa_ABVX_Risk_Zones_071226084602_1783860362.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T08:46:00", "published_display": "12 Jul 2026 08:46", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Could Be 44% Undervalued As UC Data Lands", "summary": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) is considered 44% undervalued by analysts, trading below its implied fair value of \u20ac220 despite a recent share price run and new positive data for its ulcerative colitis candidate, obefazimod. The company has also secured sufficient funding fo", "url": "https://simplywall.st/stocks/fr/pharmaceuticals-biotech/epa-abvx/abivax-societe-anonyme-shares/news/abivax-socit-anonyme-enxtpaabvx-could-be-44-undervalued-as-u", "source_name": "Simply Wall Street", "published_at": "2026-07-11T00:11:04", "published_display": "11 Jul 2026 00:11", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Buy Abivax SA Sponsored ADR (ABVX) After Golden Cross?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/buy-abivax-sa-sponsored-adr-135501149.html", "source_name": "Zacks", "published_at": "2026-07-10T13:55:01+00:00", "published_display": "10 Jul 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax CEO says $920M raise funds U.S. drug launch without Big Pharma", "summary": "Abivax CEO Marc de Garidel announced that a recent $920 million share offering provides the company with sufficient funds to independently launch its bowel disease drug, obefazimod, in the U.S. through 2029. This funding allows them to avoid partnering with a larger pharmaceutica", "url": "https://qz.com/abivax-ceo-920-million-raise-us-drug-launch-solo-071026", "source_name": "Quartz", "published_at": "2026-07-10T14:39:34", "published_display": "10 Jul 2026 14:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Piper Sandler raises Abivax stock price target to $175 on UC data", "summary": "Piper Sandler has increased its price target for Abivax (NASDAQ: ABVX) to $175 from $165, maintaining an Overweight rating, following positive ulcerative colitis data and recent equity financing. The firm boosted its 2035 U.S. ulcerative colitis revenue estimates for obefazimod t", "url": "https://www.investing.com/news/analyst-ratings/piper-sandler-raises-abivax-stock-price-target-to-175-on-uc-data-93CH-4784521", "source_name": "Investing.com", "published_at": "2026-07-10T11:40:34", "published_display": "10 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC", "summary": "Abivax secured $920 million in funding, allowing the French biotech to independently launch its bowel disease drug, obefazimod, in the U.S. without needing a Big Pharma acquisition. CEO Marc de Garidel stated this funding provides cash until late 2029 and positions the company fo", "url": "https://www.cnbc.com/2026/07/10/abivax-stock-takeover-us-launch-obefazimod-ulcerative-colitis.html", "source_name": "CNBC", "published_at": "2026-07-10T10:12:42", "published_display": "10 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Best defense is the offence, says Abivax CEO after takeover speculation", "summary": "Abivax CEO Marc de Garidel discussed the company's clinical trials and recent takeover speculation. He stated that \"Best defense is the offense\" in response to questions about the company's strategy amid these speculations.", "url": "https://www.cnbc.com/video/2026/07/10/abivax-ceo-best-defense-is-the-offence.html", "source_name": "CNBC", "published_at": "2026-07-10T10:12:42", "published_display": "10 Jul 2026 10:12", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax: Wall Street Catches Up to the Data", "summary": "Shares of Abivax (NASDAQ: ABVX) surged over 40% after positive Phase 3 trial results for its ulcerative colitis drug, Obefazimod, and a successful $920 million share offering. Despite an initial dip due to a cancer-related safety signal, subsequent data reinforced the drug's safe", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ABBV/pressreleases/3188479/abivax-wall-street-catches-up-to-the-data/", "source_name": "The Globe and Mail", "published_at": "2026-07-08T11:40:09", "published_display": "08 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sofinnova Crossover I cuts Abivax (ABVX) holding to 3.1% after share sales", "summary": "Sofinnova Crossover I SLP and related parties have reduced their stake in Abivax S.A. (ABVX) to approximately 3.1% of outstanding ordinary shares. This reduction followed a series of open-market sales of American Depositary Shares (ADSs) and ordinary shares between June 30 and Ju", "url": "https://www.stocktitan.net/sec-filings/ABVX/schedule-13d-a-abivax-s-a-amended-major-shareholder-report-63900733e297.html", "source_name": "Stock Titan", "published_at": "2026-07-07T01:40:49", "published_display": "07 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Closes $920 Million ADS Offering", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/abivax-closes-920-million-ads-202120337.html", "source_name": "MT Newswires", "published_at": "2026-07-06T20:21:20+00:00", "published_display": "06 Jul 2026 20:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Announces Closing of $920 Million Public Offering", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abivax-announces-closing-920-million-200500963.html", "source_name": "GlobeNewswire", "published_at": "2026-07-06T20:05:00+00:00", "published_display": "06 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Rebounds, but Obefazimod Unlikely to Replace JAK Inhibitors, Wedbush Says", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/abivax-rebounds-obefazimod-unlikely-replace-151247990.html", "source_name": "MT Newswires", "published_at": "2026-07-06T15:12:47+00:00", "published_display": "06 Jul 2026 15:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Abivax to $140 From $110, Keeps Neutral Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-raises-price-target-abivax-105235369.html", "source_name": "MT Newswires", "published_at": "2026-07-06T10:52:35+00:00", "published_display": "06 Jul 2026 10:52", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: New UC Data Sparks Smoother Sailing for Abivax", "summary": "Shares of French biotech company Abivax surged after the company released positive new data from its Phase III maintenance program for obefazimod, its lead candidate for ulcerative colitis. The data showed meaningful clinical benefit and, crucially, no new safety signals, easing ", "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-new-uc-data-sparks-smoother-sailing-for-abivax/", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-07-05T21:16:12", "published_display": "05 Jul 2026 21:16", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is ABIVAX Soci\u00e9t\u00e9 Anonyme (ABVX) A Good Stock To Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNY2FmMkpYbDMyZnhPRVVuODMzNEFXNTdtNGtUeDd4MHJaOHZBWHh4cDZiUDRpSmZ1cm9Oa0VjcXdKLUJSbVNFMzRRc290Zk5ybWZlU05JOVVNcm55akZpdDhERFdUWjFUMDZfNnhDaHBPamd5ZlZlVFBKOEQ2RjhuX29SSXA1T3lGYk9SU2RhOEtYSm5jdGc?oc=5", "source_name": "Market source", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Eyes Over Six-Month High As US Commercialization Plans Gain Momentum \u2013 Retail Eyes Potential Buyout", "summary": "Abivax (ABVX) shares are nearing a six-month high after underwriters fully exercised an option to purchase an additional 960,000 American depositary shares, raising total proceeds to $874.1 million. The funds will support the potential U.S. commercialization of its lead drug Obef", "url": "https://stocktwits.com/news-articles/markets/equity/why-abvx-stock-is-rising-abivax-920-million-offering/cZme09eR7S7", "source_name": "Stocktwits", "published_at": "2026-07-02T10:09:12", "published_display": "02 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Prices $800M Offering Of ADS \u2013 Here\u2019s A Look At Some Key Figures", "summary": "Abivax announced the pricing of an upsized underwritten public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, increasing the offering size from $600 million to $800 million. The company expects these proceeds, combined with existing cash, to extend its op", "url": "https://stocktwits.com/news-articles/markets/equity/abvx-stock-offering-ads-800-million/cZm3LXMR7KU", "source_name": "Stocktwits", "published_at": "2026-07-02T09:09:48", "published_display": "02 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet", "summary": "Abivax shares continued to rise after the French biotech firm announced an upsized stock offering to strengthen its balance sheet. This move follows positive clinical trial data for its lead drug, obefazimod, which is being developed to treat inflammatory bowel diseases. The comp", "url": "https://www.wsj.com/finance/stocks/abivax-shares-continue-climbing-after-biotech-firm-moves-to-bolster-balance-sheet-3c1be30a", "source_name": "WSJ", "published_at": "2026-07-02T09:09:12", "published_display": "02 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Eyes Over Six-Month High As Investors Double Down On Abivax's Lead Drug Bet \u2013 Buyout Chatter Builds", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQQkRXQy1LMXZFVUlQNUJ6VmFVUEZKcmFLUHNjWFhFM0VLVFZ0UjhuNE5Xd2JTc1B0Z2hIa1lXTGRtV09FV0pGMXcwTUNoeDRSajdiSmxKQjBacVBzWEFFblVUVUpqNWwwY055M2RmRk9LQ1lkSzNSU0lIblQ2ZmVCWnhYMWx1WlBNSHUxQWQ1M3U1bXM?oc=5", "source_name": "Market source", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares surge as worries subside over immune drug\u2019s cancer risk", "summary": "Shares of Abivax surged by nearly 40% after the release of supplementary Phase 3 data for its inflammatory bowel disease drug, obefazimod, which alleviated investor concerns about increased cancer risk. The company stated that cancer rates observed in its trials were consistent w", "url": "https://www.biopharmadive.com/news/abivax-obefazimod-Phase3-safety-data-cancer-ulcerative-colitis/824196/", "source_name": "BioPharma Dive", "published_at": "2026-07-01T22:12:12", "published_display": "01 Jul 2026 22:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax stock surges on obefazimod safety data, cancer concerns", "summary": "Abivax's stock price experienced a surge following the release of safety data for its drug candidate, obefazimod. This positive development likely addressed some previous concerns, potentially including those related to cancer.", "url": "https://qz.com/abivax-stock-obefazimod-trial-data-cancer-safety-063026", "source_name": "Quartz", "published_at": "2026-07-01T21:10:30", "published_display": "01 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax raises $800M as dilution hits 8% and cash reaches 2029", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNzA2RWlWV2VJcFB2eFI2WmtwNm1BMFVFZGhIN2dvaGhndmRNdDdaQmdaRzRyaTVWNEpNRnE3cXgtNktQSXlHekppN0pNbWM1MW41SWpWbXZtRHFNNHFBZzFyWmhLenptSXoyUGg3WXVLZXYyb29HNFduSWFlZlZPMmZTaThKdFJ2dGc1Q1AyM0sybUVHSTA3STNlNHJpTGpHV2pwZmZWS2tndWJBTHdNRTNjWjF3QnFSSkxZ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From Cancer Scare to Comeback, Abivax Shares Erase a Month of Losses in a Day", "summary": "Abivax shares surged over 38% after new Phase 3 data for its ulcerative colitis drug, obefazimod, eased cancer-safety fears that had previously caused a significant stock crash. The data showed durable remission with no new safety signals, reassuring investors. While some analyst", "url": "https://finance.yahoo.com/healthcare/articles/cancer-scare-comeback-abivax-shares-045625979.html", "source_name": "Market source", "published_at": "2026-07-01T05:10:29", "published_display": "01 Jul 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks making the biggest moves midday: AeroVironment, Abivax, Astera Labs, Watts Water Technologies & more", "summary": "This article details the biggest stock movements midday, including AeroVironment's rally due to strong earnings and revenue, Abivax's surge on positive ulcerative colitis treatment data, and Watts Water Technologies' jump after an analyst upgrade. Other companies like Astera Labs", "url": "https://www.cnbc.com/2026/06/30/stocks-making-the-biggest-moves-midday-avav-abvx-alab-wts.html", "source_name": "CNBC", "published_at": "2026-06-30T17:10:29", "published_display": "30 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABVX Stock Whipsaws As Obefazimod Delivers Standout Phase 3 Data", "summary": "Abivax SA (ABVX) stock experienced significant volatility, whipsawing after announcing positive Phase 3 data for its ulcerative colitis drug, obefazimod. The drug showed strong remission rates compared to placebo, meeting key endpoints, but concerns about malignancy cases at the ", "url": "https://stockstotrade.com/news/abivax-sa-abvx-news-2026_06_30-2/", "source_name": "StocksToTrade", "published_at": "2026-06-30T16:10:29", "published_display": "30 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares jump as updated trial data eases safety concerns", "summary": "Abivax shares surged over 40% after releasing updated safety data for its investigational ulcerative colitis drug, obefazimod. The new analysis showed malignancy rates consistent with background rates in ulcerative colitis patients, easing previous safety concerns that had caused", "url": "https://www.proactiveinvestors.com/companies/news/1094736/abivax-shares-jump-as-updated-trial-data-eases-safety-concerns-1094736.html", "source_name": "Proactive financial news", "published_at": "2026-06-30T13:15:00", "published_display": "30 Jun 2026 13:15", "sentiment": "positive", "sentiment_pct": 73, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Slides as Investors Continue to Weigh Obefazimod Safety Questions | ABVX Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQOFduOWFvX2RveHI2N0VNSzA2Y3k5YVB4Rm4xNEw0UWhDV2NKejdMYkVyRWM0TndyNjVsUzhodmRScF9IOE42dEJjUVh6N0JCNVJrb1E5ZnJSa2JFTzJBV2I2VTNoZlM2UWVVNzhyM2FIdTEwS0laWGx6RHhFU0JWUk1YRmVsVHVnYW5ra091R3ZzVWxGblFMSk00X2w2SGptY1NRU3d2dlo?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax (ABVX) Jumps 16% on Bargain-Hunting", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxOUTdTalFmbGFneHFEUGVNTU9NeHQ4NjQ1aHdTa2JRdlphcWFWSl9zcUJvUDd0Y1FZMHMtemdhckFWaF80UzVmWUpwSFRqcDNaSzFjWmdGeFI2N2pIcU9wb3AxQlRNVDg1a09DOEpTa0p2bEh3S0FsMVppMHVLdlV4aXhmQ0hIM3BkUTItbDQyWTlKb0tzMDcySA?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax SA Sponsored ADR (ABVX) Loses 41.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQb0dRd05xclZYOWRvTjVNdS1wWVJFRkhDVnRqMHVjR3V5a29OOFBVTUtydFlpel9zYVJyeF9PQWY4b1l6c2NYQ2c0Z2F2OU0yS25QMlJVeV9FUEE4QlAtX2N0OHhfdzZWeV9DSnI4ZEJoa3dON0M3UGE3ZzhSd0lHckMtem9LLURkOEZjcGl5c0N5UzVQXzhleQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax Drops 32% On Cancer Signal: Jefferies Warns Of \u2018Real\u2019 Overhang But Retail Calls Selloff An \u2018Overreaction\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNNGg1aFFHdVVCTWdMbnFlX1hVamZMcTU2ZWt5WDFJekhCSW00NnVqZmp3UW55UHQ4b1FMYnUyUm9SamRUUTQxNnY0YkVROC1DUkZpUjZVSXB3eTFlUnFfbTRTY2dESXJ5c1lZMjM0ZnM3X2E2cW5uTzRqc0NCXzEzOHRFbG9UdXJYcVE1bGExV29zYjl6ZnNzVzRB?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abivax shares sink after key trial results for inflammatory bowel drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxQLUdsbXNZM0dVUzlnZmd1TEhBLVUxcjR6RFZZY0RleU1seXhjTktWN0xKcHhzbENpRXl4dXNmN19NbEVTdVFMVFpXV1dHQ2ItYUFWTHdyR1laUlFQd1NRWTBwWklSZ3RpMXdfN0xGVlhKQVFvanZBbENvNnlna3NrVHVaTXFNWHh5VFVCLU1jZEhuaUZVeG5abU1yb3N3S1NFUUJnOGVZZl9renN1a2N4WVFIVXRVR0J6aTlWWnRvUlZZLXVKY0kyeGNNN203bGR3TVR4Sg?oc=5", "source_name": "Reuters", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Abivax SA Sponsored ADR (ABVX) a Strong Momentum Stock: Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQYXVfVjVSdXNiYmluVFFXbGZMaVZuMVp1RE9xQ0NfXzA5QUljd25GVjI0Tzh4VERiXzZpVUxDN3ZPa21MYUlVc0xKVkxMX212QnFLa3haRXZkTFIxR05pb01CN0FhRmVtdGQtRnVERkdZUmY5MmhXRHF3X0laR1o0ZDdJcUtGYnprdVlkaFJkcUx0bWdLcDlIblVn?oc=5", "source_name": "Market source", "published_at": "2026-05-28T07:00:00+00:00", "published_display": "28 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Is Up 6.9% After Long-Term Obefazimod Data And Q1 Results - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNMHVvVkFYSTg1NFFXYk42QkFUX1YyLXZvY0dSSHJnQkxSZzcyZmY2Z1phOTJiWVhnZFdlbjJLaEJsekl6UFZYNTlkMklkeUNFT1dfREpNMHowbDZ1QXRkWTBHMDU4aWVHQzNWdGRJd1FITk5zd1VtVGhxV2otNUI2WHNLOExORWxEZzFDMVRBeTNWOVF3cGtrSkV2QWRSZw?oc=5", "source_name": "Market source", "published_at": "2026-05-24T07:00:00+00:00", "published_display": "24 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing ABIVAX Soci\u00e9t\u00e9 Anonyme (ENXTPA:ABVX) Valuation After Recent Share Price Softness And Conflicting Metrics", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPcF9UUjJDZHVTaHo3ZHRaaUFnWkVrdlk3RmhCVmVFTDZ3d3l1a2FIdjgzYTlTUzh4MjA3aWMtWWM2cTJsY28xTlF3em1NSHZ4Z3liNWZYVktWdGUyMVlLQ3lPd3JiVHVBaVRMYlAxNjJRR3c0YnpmOXIzdEZFM282U3ktRWI3T2RZc0Vwam5GWTAwVjB3RGs3VFp5blM?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX (ABVX) Announces $90M Agreement to Repurchase Royalty Certificates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSUpYNU8yV3kyVVF2NXZnNU1MMWtXRnNCakFfQ3lnREE4a2c5bnNOU2xBS2VXZnU4R25nekY3bnY3UWhQY0wtWmxqa01PV1d3NHlQQzZ2ODRENkZuclNpQ2p5ZmxtdDFTQ09FZ3RtQUlSOV9JSU1mN2sxcktqRG9BT0J0TlVaSEotdWViYUFRaW9mZnVaSW5MWU1vTHhCODlURWc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABIVAX (ABVX) Appoints Michael Nesrallah as Chief Commercial Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaE5ybTFpYkl2V3hUTkJGRmh6Q0xqaTZPbzN3TTFlT3hjd3hudWF0TGI2aEdCemtnSjNndVduRFAyNmdhN2ZLWnNXeG02NkVBRDlraElPbDU5VlVLZENOYno2NnFOUEprVWVxdEl3SzB2WE1tam5BOVhNM2Z0YlRSdm9GVXZKVXBHODFCVGJxVWVzOVR1TVJjeUhHN2RPd3dTU3B0Q2lR?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 57, "sentiment_summary": {"positive": 27, "negative": 4, "neutral": 26, "score": 60, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.8, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 8.81, "count": 17}, {"event": "deals", "label": "Deals and strategy", "weight": 2.55, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}], "positive_events": 27, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 136.65, "latest_week": "2026-07-17", "one_week_move": -2.3, "four_week_move": 37.8, "twelve_week_move": 19.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.027868, "market_dynamics_buy_signal": false, "relative_strength": 13.700449, "fair_value_gap": 199.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 58.8193, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +37.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 17}, {"label": "MarketBeat", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "CNBC", "count": 3}, {"label": "MSN", "count": 2}, {"label": "Quartz", "count": 2}, {"label": "Stock Titan", "count": 2}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 17}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Macro sensitivity", "count": 2}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "6", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.3% over one week, +37.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Abivax SA Sponsored ADR $ABVX Shares Bought by Jennison Associates LLC"}], "updated_at": "2026-07-21T14:19:27.649676+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}